180 related articles for article (PubMed ID: 21105122)
1. Bladder cancer: current management and opportunities for a personalized approach.
Galsky MD; Hall SJ
Mt Sinai J Med; 2010; 77(6):587-96. PubMed ID: 21105122
[TBL] [Abstract][Full Text] [Related]
2. Behavior of urothelial carcinoma with respect to anatomical location.
Catto JW; Yates DR; Rehman I; Azzouzi AR; Patterson J; Sibony M; Cussenot O; Hamdy FC
J Urol; 2007 May; 177(5):1715-20. PubMed ID: 17437794
[TBL] [Abstract][Full Text] [Related]
3. Urothelial cancers: using biology to improve outcomes.
Pezaro C; Liew MS; Davis ID
Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
[TBL] [Abstract][Full Text] [Related]
4. Treatment of muscle-invasive bladder cancer: progress and new challenges.
Herring JC; Kamat AM
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1047-56. PubMed ID: 15606332
[TBL] [Abstract][Full Text] [Related]
5. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
6. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.
Ahmed HU; Arya M; Patel HR
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1011-22. PubMed ID: 16336092
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
[TBL] [Abstract][Full Text] [Related]
8. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.
Amiel GE; Lerner SP
Expert Rev Anticancer Ther; 2006 Feb; 6(2):281-91. PubMed ID: 16445380
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
10. Invasive micropapillary urothelial carcinoma of the bladder.
Lopez-Beltran A; Montironi R; Blanca A; Cheng L
Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
[TBL] [Abstract][Full Text] [Related]
11. Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment.
Steinberg GD; Trump DL; Cummings KB
Urol Clin North Am; 1992 Nov; 19(4):735-46. PubMed ID: 1279877
[TBL] [Abstract][Full Text] [Related]
12. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
Pollera CF; Nelli F
Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer.
Raghavan D
Cancer; 2003 Apr; 97(8 Suppl):2083-9. PubMed ID: 12673700
[TBL] [Abstract][Full Text] [Related]
14. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of invasive bladder cancers: histological and molecular markers.
Liebert M; Seigne J
Semin Urol Oncol; 1996 May; 14(2):62-72. PubMed ID: 8734733
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer.
Gwynn ES; Clark PE
Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
[TBL] [Abstract][Full Text] [Related]
18. [Current chemotherapy of locally advanced or metastatic bladder tumors].
Dourthe LM; Ceccaldi B; Fournier R; Houlgatte A; Merrer J
Ann Urol (Paris); 2000 Feb; 34(1):3-8. PubMed ID: 10763417
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
[TBL] [Abstract][Full Text] [Related]
20. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
